Indian American Firm Advances Stem Cell Therapy For Type II Diabetes

India-West Staff Reporter

SAN DIEGO, CA—The Global Institute of Stem Cell Therapy and Research (GIOSTAR), based here which is focused on developing innovative therapies to improve the care of patients with Type II diabetes has announced that the U.S. Food and Drug Administration (FDA) has cleared its application to begin a Phase-2 clinical trial for DT2-SCT, a novel stem cell therapy designed to treat the disease.

This treatment uses autologous mesenchymal stem cells to address the damage caused by the disease, offering hope for diabetes patients with fewer side effects, the company said.

Diabetes has become a global health crisis, affecting over one billion people worldwide and costing the healthcare system over a trillion dollars annually. Company CEO, Deven Patel, emphasized that if the clinical trials are successful, the company plans to make this treatment affordable for the masses, leveraging its existing infrastructure of hospitals and research centers to capture a significant global market share.

Dr. Anand Srivastava, the chairman and cofounder of Giostar, explained that the DT2-SCT therapy uses stem cells from the patient’s own tissue to target the damage caused by diabetes.

The Phase-2 clinical trial for DT2-SCT is expected to be completed within 12 to 18 months, with participants enrolling at several sites across the U.S. Patel noted that while lifestyle changes are crucial in managing diabetes, certain genetic factors make it difficult for many individuals to avoid developing the disease.